Lisa Silverman

1 month ago | jdsupra.com | Emily Roberts |Lisa Silverman

On March 13, 2025, the Federal Circuit issued a decision in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., No. 23-2254 (Fed. Cir. 2025) that clarifies how patent term extension (PTE) is calculated for reissue patents.

Dec 3, 2024 | jdsupra.com | Lisa Silverman

Dec 3, 2024 | law360.co.uk | Lisa Silverman |Qiwen Zhong

ADVERTISEMENT Don't want ads? Subscribe or login now. By Lisa Silverman and Qiwen Zhong ( December 3, 2024, 10:13 AM EST) -- A recent decision by the Patent Trial and Appeal Board sheds light on certain pitfalls patent applicants may encounter when submitting declarations under Title 37 of the Code of Federal Regulations, Section 1.132....

Dec 3, 2024 | law360.co.uk | Lisa Silverman |Qiwen Zhong

ADVERTISEMENT Don't want ads? Subscribe or login now. By Lisa Silverman and Qiwen Zhong ( December 3, 2024, 10:13 AM EST) -- A recent decision by the Patent Trial and Appeal Board sheds light on certain pitfalls patent applicants may encounter when submitting declarations under Title 37 of the Code of Federal Regulations, Section 1.132....

Oct 29, 2024 | jdsupra.com | Lisa Silverman |Qiwen Zhong

A recent decision by the Patent Trial and Appeal Board (PTAB) sheds light on certain pitfalls patent applicants may encounter when submitting declarations under 37 C.F.R. § 1.132 (“Rule 132 Declarations”). Rule 132 Declarations are frequently used in life sciences patent prosecution to submit data in support of a patent application. They are an important tool for rebutting obviousness rejections raised under 35 U.S.C. § 103 by establishing that an applicant’s invention produces unexpected results.